Literature DB >> 28132687

Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.

Markus Riessland1, Anna Kaczmarek1, Svenja Schneider1, Kathryn J Swoboda2, Heiko Löhr3, Cathleen Bradler4, Vanessa Grysko1, Maria Dimitriadi5, Seyyedmohsen Hosseinibarkooie1, Laura Torres-Benito1, Miriam Peters1, Aaradhita Upadhyay1, Nasim Biglari1, Sandra Kröber1, Irmgard Hölker1, Lutz Garbes1, Christian Gilissen6, Alexander Hoischen6, Gudrun Nürnberg7, Peter Nürnberg7, Michael Walter8, Frank Rigo9, C Frank Bennett9, Min Jeong Kye10, Anne C Hart5, Matthias Hammerschmidt11, Peter Kloppenburg4, Brunhilde Wirth12.   

Abstract

Homozygous SMN1 loss causes spinal muscular atrophy (SMA), the most common lethal genetic childhood motor neuron disease. SMN1 encodes SMN, a ubiquitous housekeeping protein, which makes the primarily motor neuron-specific phenotype rather unexpected. SMA-affected individuals harbor low SMN expression from one to six SMN2 copies, which is insufficient to functionally compensate for SMN1 loss. However, rarely individuals with homozygous absence of SMN1 and only three to four SMN2 copies are fully asymptomatic, suggesting protection through genetic modifier(s). Previously, we identified plastin 3 (PLS3) overexpression as an SMA protective modifier in humans and showed that SMN deficit impairs endocytosis, which is rescued by elevated PLS3 levels. Here, we identify reduction of the neuronal calcium sensor Neurocalcin delta (NCALD) as a protective SMA modifier in five asymptomatic SMN1-deleted individuals carrying only four SMN2 copies. We demonstrate that NCALD is a Ca2+-dependent negative regulator of endocytosis, as NCALD knockdown improves endocytosis in SMA models and ameliorates pharmacologically induced endocytosis defects in zebrafish. Importantly, NCALD knockdown effectively ameliorates SMA-associated pathological defects across species, including worm, zebrafish, and mouse. In conclusion, our study identifies a previously unknown protective SMA modifier in humans, demonstrates modifier impact in three different SMA animal models, and suggests a potential combinatorial therapeutic strategy to efficiently treat SMA. Since both protective modifiers restore endocytosis, our results confirm that endocytosis is a major cellular mechanism perturbed in SMA and emphasize the power of protective modifiers for understanding disease mechanism and developing therapies.
Copyright © 2017 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NCALD; PLS3; SMA; SMN1; SMN2; asymptomatic; endocytosis; genetic modifier; incomplete penetrance; neuronal sensor protein; spinal muscular dystrophy

Mesh:

Substances:

Year:  2017        PMID: 28132687      PMCID: PMC5294679          DOI: 10.1016/j.ajhg.2017.01.005

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  94 in total

Review 1.  Neurotransmitter release at central synapses.

Authors:  Charles F Stevens
Journal:  Neuron       Date:  2003-10-09       Impact factor: 17.173

2.  The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins.

Authors:  Q Liu; U Fischer; F Wang; G Dreyfuss
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

3.  Dynasore, a cell-permeable inhibitor of dynamin.

Authors:  Eric Macia; Marcelo Ehrlich; Ramiro Massol; Emmanuel Boucrot; Christian Brunner; Tomas Kirchhausen
Journal:  Dev Cell       Date:  2006-06       Impact factor: 12.270

4.  Molecular defects in the motor adaptor BICD2 cause proximal spinal muscular atrophy with autosomal-dominant inheritance.

Authors:  Kristien Peeters; Ivan Litvinenko; Bob Asselbergh; Leonardo Almeida-Souza; Teodora Chamova; Thomas Geuens; Elke Ydens; Magdalena Zimoń; Joy Irobi; Els De Vriendt; Vicky De Winter; Tinne Ooms; Vincent Timmerman; Ivailo Tournev; Albena Jordanova
Journal:  Am J Hum Genet       Date:  2013-05-09       Impact factor: 11.025

Review 5.  Spinal muscular atrophy--clinical and genetic correlations.

Authors:  K Zerres; B Wirth; S Rudnik-Schöneborn
Journal:  Neuromuscul Disord       Date:  1997-05       Impact factor: 4.296

6.  Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent.

Authors:  Monir Shababi; Zhihua Feng; Eric Villalon; Christine M Sibigtroth; Erkan Y Osman; Madeline R Miller; Patricka A Williams-Simon; Abby Lombardi; Thalia H Sass; Arleigh K Atkinson; Michael L Garcia; Chien-Ping Ko; Christian L Lorson
Journal:  Mol Ther       Date:  2016-02-10       Impact factor: 11.454

Review 7.  An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).

Authors:  B Wirth
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2.

Authors:  Thomas W Prior; Kathryn J Swoboda; H Denman Scott; Ashley Q Hejmanowski
Journal:  Am J Med Genet A       Date:  2004-10-15       Impact factor: 2.802

9.  Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy.

Authors:  Juliane Ramser; Mary Ellen Ahearn; Claus Lenski; Kemal O Yariz; Heide Hellebrand; Michael von Rhein; Robin D Clark; Rita K Schmutzler; Peter Lichtner; Eric P Hoffman; Alfons Meindl; Lisa Baumbach-Reardon
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

10.  Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia.

Authors:  Emily C Oates; Alexander M Rossor; Majid Hafezparast; Michael Gonzalez; Fiorella Speziani; Daniel G MacArthur; Monkol Lek; Ellen Cottenie; Mariacristina Scoto; A Reghan Foley; Matthew Hurles; Henry Houlden; Linda Greensmith; Michaela Auer-Grumbach; Thomas R Pieber; Tim M Strom; Rebecca Schule; David N Herrmann; Janet E Sowden; Gyula Acsadi; Manoj P Menezes; Nigel F Clarke; Stephan Züchner; Francesco Muntoni; Kathryn N North; Mary M Reilly
Journal:  Am J Hum Genet       Date:  2013-05-09       Impact factor: 11.025

View more
  63 in total

1.  Phenotypic extremes of BICD2-opathies: from lethal, congenital muscular atrophy with arthrogryposis to asymptomatic with subclinical features.

Authors:  Markus Storbeck; Beate Horsberg Eriksen; Andreas Unger; Irmgard Hölker; Ingvild Aukrust; Lilian A Martínez-Carrera; Wolfgang A Linke; Andreas Ferbert; Raoul Heller; Matthias Vorgerd; Gunnar Houge; Brunhilde Wirth
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.

Authors:  Laura Torres-Benito; Svenja Schneider; Roman Rombo; Karen K Ling; Vanessa Grysko; Aaradhita Upadhyay; Natalia L Kononenko; Frank Rigo; C Frank Bennett; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2019-06-20       Impact factor: 11.025

3.  Abnormal Golgi morphology and decreased COPI function in cells with low levels of SMN.

Authors:  S K Custer; J N Foster; J W Astroski; E J Androphy
Journal:  Brain Res       Date:  2018-11-05       Impact factor: 3.252

4.  AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.

Authors:  E Villalón; R A Kline; C E Smith; Z C Lorson; E Y Osman; S O'Day; L M Murray; C L Lorson
Journal:  Hum Mol Genet       Date:  2019-11-15       Impact factor: 6.150

Review 5.  Model organism data evolving in support of translational medicine.

Authors:  Douglas G Howe; Judith A Blake; Yvonne M Bradford; Carol J Bult; Brian R Calvi; Stacia R Engel; James A Kadin; Thomas C Kaufman; Ranjana Kishore; Stanley J F Laulederkind; Suzanna E Lewis; Sierra A T Moxon; Joel E Richardson; Cynthia Smith
Journal:  Lab Anim (NY)       Date:  2018-09-17       Impact factor: 12.625

Review 6.  Calcium Sensors in Neuronal Function and Dysfunction.

Authors:  Robert D Burgoyne; Nordine Helassa; Hannah V McCue; Lee P Haynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-05-01       Impact factor: 10.005

7.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

Review 8.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

9.  Histone demethylase KDM5C is a SAHA-sensitive central hub at the crossroads of transcriptional axes involved in multiple neurodevelopmental disorders.

Authors:  Loredana Poeta; Agnese Padula; Benedetta Attianese; Mariaelena Valentino; Lucia Verrillo; Stefania Filosa; Cheryl Shoubridge; Adriano Barra; Charles E Schwartz; Jesper Christensen; Hans van Bokhoven; Kristian Helin; Maria Brigida Lioi; Patrick Collombat; Jozef Gecz; Lucia Altucci; Elia Di Schiavi; Maria Giuseppina Miano
Journal:  Hum Mol Genet       Date:  2019-12-15       Impact factor: 6.150

Review 10.  From phenologs to silent suppressors: Identifying potential therapeutic targets for human disease.

Authors:  Andy Golden
Journal:  Mol Reprod Dev       Date:  2017-10-03       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.